Fake Ozempic Targets Weight-Loss Market: Forged Batches An International Concern
Portfolio Pulse from Michael Juliano
Criminals are distributing fake versions of the weight-loss drug Ozempic, made by Novo Nordisk, by forging batch numbers. This has led to a decline in stock prices for major pharmaceutical companies involved in the weight-loss drug market.

September 05, 2024 | 5:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pfizer's stock gained 0.51%, possibly due to its lesser involvement in the weight-loss drug market compared to others.
Pfizer's stock increase suggests it is less affected by the counterfeiting issues plaguing the weight-loss drug market.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 40
NEGATIVE IMPACT
Amgen's stock dropped 2.53% amid broader concerns in the pharmaceutical sector related to drug counterfeiting.
While not directly involved in the Ozempic counterfeiting, Amgen's stock is affected by the overall negative sentiment in the pharmaceutical sector.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 60
NEGATIVE IMPACT
Eli Lilly's stock slipped 3.81% as the weight-loss drug market faces counterfeiting issues, potentially affecting their product Mounjaro.
Eli Lilly is mentioned as another company affected by counterfeiting in the weight-loss drug market, which could impact their sales and market perception.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 80
NEGATIVE IMPACT
Novo Nordisk's stock fell 2.74% due to concerns over fake Ozempic drugs, which could impact their market share and brand reputation.
The news directly involves Novo Nordisk as the manufacturer of Ozempic, which is being counterfeited. This could lead to decreased consumer trust and potential financial losses.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
NEGATIVE IMPACT
Viking Therapeutics' stock slipped 2.80%, reflecting broader market concerns in the pharmaceutical sector.
Viking Therapeutics is indirectly affected by the negative sentiment in the pharmaceutical sector due to counterfeiting issues.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 50